The first CAR T cells targeting BCMA, also known as TNFRSF17 or CD296, were pre-clinically tested in 2013 on myeloma cell lines and showed a marked activity against them (Figure 3) [66]. Here, TNFRSF17 is linked to plasma cell myeloma.